A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder.

ABSTRACT:

Background

Even when patients experience remission with antidepressants, many continue to report anger attacks and excessive irritability despite continued treatment. Iloperidone antagonizes 5-HT-2a, D2, and alpha-1 receptors, which can have anti-aggressive effects. We examined iloperidone's safety and efficacy as an augmentation agent in outpatients with partially remitted major depressive disorder (MDD) with residual symptoms of anger and irritability.

Methods

A total of 13 outpatients with partially remitted MDD [currently treated with selective serotonin reuptake inhibitors (SSRIs)] received four weeks of iloperidone or placebo, followed by one week of washout. Patients were then crossed over to the other treatment arm for 4 weeks. Treatment arms were randomized and doub

SUBMITTER: Ionescu DF 

PROVIDER: S-EPMC4749740 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature